Illumina (NASDAQ:ILMN – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations for Illumina and MaxCyte, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Illumina | 3 | 6 | 10 | 0 | 2.37 |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
Illumina currently has a consensus target price of $244.24, suggesting a potential upside of 19.50%. MaxCyte has a consensus target price of $4.50, suggesting a potential upside of 296.48%. Given MaxCyte’s higher possible upside, analysts plainly believe MaxCyte is more favorable than Illumina.
Risk & Volatility
Insider and Institutional Ownership
89.4% of Illumina shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Illumina and MaxCyte”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Illumina | $4.34 billion | 7.12 | $850.00 million | $5.81 | 35.18 |
| MaxCyte | $33.03 million | 3.55 | -$44.63 million | ($0.26) | -4.37 |
Illumina has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Illumina and MaxCyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Illumina | 19.72% | 28.38% | 12.11% |
| MaxCyte | -81.40% | -15.05% | -12.79% |
Summary
Illumina beats MaxCyte on 11 of the 14 factors compared between the two stocks.
About Illumina
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
About MaxCyte
MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
